Thrombophilia and pregnancy loss

Thrombosis Research

Volumn 108, Issue 4, 2002, Pages 197-202

  Brenner, Benjamin ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Low molecular weight heparin; Pregnancy loss; Thrombophilia

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

CLINICAL TRIAL; COHORT ANALYSIS; FETUS WASTAGE; FIBRIN DEPOSITION; HUMAN; INTRAUTERINE GROWTH RETARDATION; PATHOLOGY; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; THROMBOPHILIA; THROMBOSIS; VASCULAR DISEASE;

EID: 0037176132     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00390-0     Document Type: Review

References (58)

1. Salafia C.M., Minior V.K., Pezzullo J.C., Popek E.J., Rosenkrantz T.S., Vintzileos A.M. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am. J. Obstet. Gynecol. 173:1995;1049-1057.
2. Cook C.L., Pridham D.D. Recurrent pregnancy loss. Curr. Opin. Obstet. Gynecol. 7:1995;357-366.
3. Clifford K., Rai R., Watson H., Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum. Reprod. 9:1994;1328-1332.
4. Hatasaka H.H. Recurrent miscarriage: epidemiologic factors, definitions, and incidence. Clin. Obstet. Gynecol. 37:1994;625-634.
5. Raziel A., Arieli S., Bukovsky I., Caspi E., Golan A. Investigation of the uterine cavity in recurrent aborters. Fertil. Steril. 62:1994;1080-1082.
6. Sanson B.J., Friederich P.W., Simioni P., Zanardi S., Hilsman M.V., Girolami A.et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women. Thromb. Haemost. 75:1996;387-388.
7. Haverkate F., Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb. Haemost. 73:1995;151-161.
8. Rikder P.M., Miletich J.P., Buring J.E., Ariyo A.A., Price D.T., Manson J.E.et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann. Intern. Med. 128:1998;1000-1003.
9. Grandone E., Margaglione M., Colaizzo D., d'Addedda M., Cappucci G., Vecchione G.et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb. Haemost. 77:1997;822-824.
10. Brenner B., Sarig G., Weiner Z., Younis J., Blumenfeld Z., Lanir N. Thrombophilic polymorphisms in women with fetal loss. Thromb. Haemost. 82:1999;6-9.
11. Sarig G., Hoffman R., Younis J., Lanir N., Blumenfeld Z., Brenner B. Thrombophilia is common in women with pregnancy loss and is associated with late pregnancy wastage. Fertil. Steril. 77:2002;342-347.
12. Dizon-Townson D.S., Kinney S., Branch D.W., Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J. Reprod. Immunol. 34:1997;217-223.
13. Roque H., Paidas M., Rebarber A., Maturi R.J., O'Neill L., Kuczynski E. Maternal thrombophilia is associated with second and third trimester fetal death. Am. J. Obstet. Gynecol. 184:2001;S27. [abst 0060].
14. Younis J.S., Brenner B., Ohel G., Tal J., Lanir N., Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can with first-as well as second-trimester recurrent pregnancy loss. Am. J. Reprod. Immunol. 43:2000;31-35.
15. Wramsby M.L., Sten-Linder M., Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil. Steril. 74:2000;987-991.
16. Meinardi J.R., Middeldorp S., de Kam P.J., Koopman M.M.W., van Pampus E.C.M., Hamulyak K.et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann. Intern. Med. 130:1999;736-739.
17. Tormene D., Simioni P., Prandoni P., Luni S., Innella B., Sabbion P.et al. The risk of fetal loss in family member of probands with factor V Leiden mutation. Thromb. Haemost. 82:1999;1237-1239.
18. Eichinger S., Weltermann A., Philipp K., Hafner E., Kaider A., Kittl E.M.et al. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb. Haemost. 82:1999;1232-1236.
19. Clark P., Brennand J., Conkie J.A., McCall D., Greer I.A., Walker I.D. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb. Haemost. 79:1998;1166-1170.
20. Kjelberg U., Andersson N.E., Rosen S., Tengborn L., Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb. Haemost. 81:1999;527-531.
21. Tal J., Schliamser L.M., Leibovitz Z., Ohel G., Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum. Reprod. 14:1999;1624-1627.
22. Brenner B., Mandel H., Lanir N., Younis J., Rothbart H., Ohel G.et al. Activated protein C resistance can be associated with recurrent fetal loss. Br. J. Haematol. 97:1997;551-554.
23. 2-glycoprotein I igG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test. Blood. 92:1998;2993-2994.
24. Souza S.S., Ferriani R.A., Pontes A.G., Zago M.A., Franco R.F. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion. Hum. Reprod. 14:1999;2448-2450.
25. Martinelli I., Taioli E., Cetin I., Marinoni A., Gerosa S., Villa M.V.et al. Mutations in coagulation factors in women with unexplained late fetal loss. N. Engl. J. Med. 343:2000;1015-1018.
26. de Vries J.I.P., Dekker G.A., Huijgens P.C., Jakobs C., Blomberg B.M., van Geijn H.P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br. J. Obstet. Gynaecol. 104:1997;1248-1254.
27. Goddijn-Wessel T.A., Wouters M.G., van der Molen E.F., Spuijbrock M.D., Steegers-Theunissen R.P., Blom H.J.et al. Hyper-homocysteinemia: a risk factor for placental abruption or infarction. Eur. J. Obstet. Gynecol. Rep. Biol. 66:1996;23-29.
28. Coumans A.B., Huijgens P.C., Jakobs C., Schats R., de Vries J.I., van Pampus M.G.et al. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Hum. Reprod. 14:1999;211-214.
29. Nelen W.L.D.M., Blom H.J., Ssteegers E.A.P., den Heijer M., Eskes T.K.A.B. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil. Steril. 74:2000;1196-1199.
30. Zöller B., Berntsdotter A., Garcia de Frutos P., Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3523.
31. Brenner B., Zivelin A., Lanir N., Greengard J.S., Griffin J.H., Seligsohn U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C deficient newborn with massive thrombosis. Blood. 88:1996;877-880.
32. Mandel H., Brenner B., Berant M., Rosenberg N., Lanir N., Jakobs C.et al. Coexistence of hereditary homocysteinuria and factor V Leiden - effect on thrombosis. N. Engl. J. Med. 334:1996;763-768.
33. Brenner B., Vulfsons S.L., Lanir N., Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden - impact on thrombotic diathesis. Br. J. Haematol. 94:1996;166-167.
34. Preston F.E., Rosendaal F.R., Walker I.D., Briet E., Berntorp E., Conard J.et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 348:1996;913-916.
35. Gris J.C., Quere I., Monpeyroux F., Mercier E., Ripart-Neveu S., Tailland M.L.et al. Case-control study of the frequency of thrombophilic disorders in couples with late fetal-loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb. Haemost. 81:1999;891-899.
36. Carp H., Dolitzky M., Tur-Kaspa I., Inbal A. Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. Fertil. Steril. 78(1):2002;58-62.
37. Dizon-Townson D.S., Nelson L.M., Easton K., Ward K. The factor V Leiden mutation may predispose women to severe pre-eclampsia. Am. J. Obstet. Gynecol. 175:1996;902-905.
38. Grandone E., Margaglione M., Colaizzo D.et al. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb. Haemost. 77:1997;1052-1054.
39. O'Shaughnessy K.M., Fu B., Ferraro E., Lewis I., Downing S., Morris N.H. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension. 33:1999;1338-1341.
40. De Groot C.J.M., Bloemenkamp K.W.M., Duvekot E.J., Helmerhorst F.M., Bertina R.M., Van Der Meer F.et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am. J. Obstet. Gynecol. 181:1999;975-980.
41. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., Haites N.E., Wilson B.J., Watson M.S.et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb. Haemost. 87:2002;779-785.
42. Infante-Rivard C., Rivard G.E., Yotov W.V., Genin E., Guiguet M., Weinberg C.et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N. Engl. J. Med. 347:2002;19-25.
43. Mousa H.A., Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum. Reprod. 15:2000;1830-1833.
44. Dizon-Townson D.S., Meline L., Nelson L.M., Varner M., War K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am. J. Obstet. Gynecol. 177:1997;402-405.
45. Kupferminc M.J., Eldor A., Steinman N., Many A., Bar-Am A., Jaffa A.et al. Increased frequency of genetic thrombophilias in women with complications of pregnancy. N. Engl. J. Med. 340:1999;9-13.
46. Grandone E., Margaglione M., Colaizzo D., D'Andrea G., Cappucci G., Brancaccio V.et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am. J. Obstet. Gynecol. 179:1998;1324-1328.
47. Many A., Schreiber I., Rosner S., Lessing J.B., Eldor A., Kupferminc M.J. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet. Gynecol. 98:2001;1041-1044.
48. Sanson B.J., Lensing A.W.A., Prins M.H., Ginsberg J.S.et al. Safety of low molecular weight heparin in pregnancy. Thromb. Haemost. 81:1999;668-672.
49. Gris J.C., Neveu S., Tailland M.L., Courtieu C., Mares P., Schved J.F. Use of low-molecular weight heparin (Enoxaparin) or of a phenformin-like substance (Moroxydine Chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb. Haemost. 73:1995;362-367.
50. Brenner B., Hoffman R., Blumenfeld Z., Weiner Z., Younis J. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb. Haemost. 83:2000;693-697.
51. Rai R., Cohen H., Dave M., Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 314:1997;253-257.
52. Nakabayashi M., Yamamoto S., Suzuki K. Analysis of thrombomodulin gene polymorphism in women with severe early-onset preeclampsia. Semin. Thromb. Hemost. 25:1999;473-479.
53. Franchi F., Biguzzi E., Cetin I., Fachetti F., Radaelli T., Bozzo M.et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br. J. Haematol. 114:2001;641-646.
54. Yamada H., Kato E.H., Ebina Y., Kishida T., Hoshi N., Kobashi G.et al. Factor XII deficiency in women with recurrent miscarriage. Gynecol. Obstet. Invest. 49:2000;80-83.
55. Glueck C.J., Kupferminc M.J., Fontaine R.N., Wang P., Weksler B.B., Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet. Gynecol. 97:2001;44-48.
56. Laude I., Rongieres-Bertrand C., Boyer-Neumann C., Wolf M., Mairovitz V., Hugel B.et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb. Haemost. 85:2001;18-21.
57. Sarig G., Lanir N., Hoffman R., Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss. Thromb. Haemost. 88:2002;32-36.
58. Aharon A., Lanir N., Drugan A., Brenner B. Procoagulant and anticoagulant mechanisms in human placenta are modulated by maternal antithrombotic therapy. Thromb. Haemost. (Suppl):2001, July;2991. [abst].